Buscar

01/02/2022 The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients
Dunn, WG, Gu, MXS, Fabre, MA, Cooper, J, Nomdedeu, JF, Koumas, L, Nicolaou, K, Chi, JX, Costeas, P, Vassiliou, GS. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. ANNALS OF HEMATOLOGY. 2022; 101(2)DOI:10.1007/s00277-021-04472-5. PMID:33650061. IF:3.500(Q2/5D).
14/12/2021 Engraftment characterization of risk-stratified AML in NSGS mice
de la Guardia, RD, Velasco-Hernandez, T, Gutierrez-Aguera, F, Roca-Ho, H, Molina, O, Nombela-Arrieta, C, Bataller, A, Fuster, JL, Anguita, E, Vives, S, Zamora, L, Nomdedeu, J, Gomez-Casares, MT, Ramirez-Orellana, M, Lapillonne, H, Ramos-Mejia, V, Rodriguez-Manzaneque, JC, Bueno, C, Lopez-Millan, B, Menendez, P. Engraftment characterization of risk-stratified AML in NSGS mice. Blood Advances. 2021; 5(23)DOI:10.1182/bloodadvances.2020003958. PMID:34470043. IF:7.642(Q1/3D).
10/08/2021 The evolution of hematopoietic cells under cancer therapy
Pich, O, Cortes-Bullich, A, Muinos, F, Pratcorona, M, Gonzalez-Perez, A, Lopez-Bigas, N. The evolution of hematopoietic cells under cancer therapy. Nature Communications. 2021; 12(1)DOI:10.1038/s41467-021-24858-3. PMID:34376657. IF:17.694(Q1/1D).
01/08/2021 Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I, Villamon, E, Abellan, R, Calasanz, MJ, Irigoyen, A, Sanz, G, Such, E, Mora, E, Gutierrez, M, Collado, R, Garcia-Serra, R, Vara, M, Blanco, ML, Oiartzabal, I, Alvarez, S, Bernal, T, Granada, I, Xicoy, B, Jerez, A, Calabuig, M, Diez, R, Gil, A, Diez-Campelo, M, Solano, C, Tormo, M. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. BRITISH JOURNAL OF HAEMATOLOGY. 2021; 194(4)DOI:10.1111/bjh.17675. PMID:34296432. IF:8.615(Q1/2D).